Charles Schwab Investment Management Inc I Mab Transaction History

Charles Schwab Investment Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $345,214 - $769,323	41,743 Added 123.77%	75,469 $853,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $17,179 - $64,294	1,370 Added 4.23%	33,726 $548,000
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $113,381 - $186,548	-2,504 Reduced 7.18%	32,356 $1.53 Million
Q3 2021 Nov 16, 2021	BUY	$57.18 - $84.43 $1.99 Million - $2.94 Million	34,860 New	34,860 $2.53 Million

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.